Annexon (ANNX) Expected to Announce Earnings on Monday

Annexon (NASDAQ:ANNX) is anticipated to issue its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, March 5, 2026 at 4:00 PM ET.

Annexon Stock Down 3.9%

NASDAQ ANNX opened at $4.90 on Monday. The stock has a market cap of $586.19 million, a price-to-earnings ratio of -3.48 and a beta of 1.17. Annexon has a fifty-two week low of $1.28 and a fifty-two week high of $7.18. The business has a fifty day moving average of $5.58 and a 200-day moving average of $3.96.

Key Annexon News

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

Wall Street Analysts Forecast Growth

ANNX has been the topic of several research reports. Wells Fargo & Company increased their target price on Annexon from $14.00 to $27.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 19th. Chardan Capital started coverage on shares of Annexon in a research note on Tuesday, December 23rd. They set a “buy” rating and a $16.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Annexon in a research report on Wednesday, January 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Annexon currently has an average rating of “Moderate Buy” and an average target price of $17.00.

Insider Transactions at Annexon

In other news, EVP Michael Overdorf sold 6,225 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $5.10, for a total transaction of $31,747.50. Following the sale, the executive vice president directly owned 124,464 shares in the company, valued at approximately $634,766.40. This represents a 4.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Dean Richard Artis sold 5,290 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $5.10, for a total value of $26,979.00. Following the completion of the sale, the executive vice president directly owned 123,487 shares in the company, valued at approximately $629,783.70. This trade represents a 4.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have purchased 41,230 shares of company stock valued at $177,321 and have sold 32,513 shares valued at $165,973. Insiders own 12.67% of the company’s stock.

Institutional Investors Weigh In On Annexon

Hedge funds have recently added to or reduced their stakes in the stock. CIBC Bancorp USA Inc. bought a new position in shares of Annexon during the third quarter worth about $31,000. Engineers Gate Manager LP acquired a new position in Annexon during the 2nd quarter valued at about $32,000. Landscape Capital Management L.L.C. bought a new position in Annexon in the 4th quarter worth about $50,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Annexon in the fourth quarter valued at approximately $52,000. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Annexon in the third quarter valued at approximately $56,000.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.